Last edition
News about "Ascentage Pharma "
Ascentage Pharma Gets NDA Approval for Bcl-2 Inhibitor Lisaftoclax
This NDA is based on results from a pivotal registrational Phase II study in China (APG2575CC201) that evaluated the efficacy and safety of lisaftoclax in patients with r/r CLL/SLL.
Ascentage Pharma | 18/11/2024 | By Aishwarya
Ascentage Pharma Olverembatinib Gets Approval from ISAF for Commercialization in Macau China
Ascentage Pharma has announced that its BCR-ABL1 tyrosine kinase inhibitor (TKI), olverembatinib, has been approved by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region (SAR) of the People's Republic of China.
Ascentage Pharma | 08/07/2024 | By Aishwarya | 114
Takeda Signs Option Deal with Ascentage Pharma to Get Exclusive Global License for Olverembatinib
Takeda has signed an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor.
Ascentage Pharma | 15/06/2024 | By Aishwarya | 121
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy